1. Home
  2. PBYI vs GBIO Comparison

PBYI vs GBIO Comparison

Compare PBYI & GBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PBYI
  • GBIO
  • Stock Information
  • Founded
  • PBYI 2010
  • GBIO 2016
  • Country
  • PBYI United States
  • GBIO United States
  • Employees
  • PBYI N/A
  • GBIO N/A
  • Industry
  • PBYI Biotechnology: Pharmaceutical Preparations
  • GBIO Biotechnology: Pharmaceutical Preparations
  • Sector
  • PBYI Health Care
  • GBIO Health Care
  • Exchange
  • PBYI Nasdaq
  • GBIO Nasdaq
  • Market Cap
  • PBYI 176.1M
  • GBIO 145.5M
  • IPO Year
  • PBYI N/A
  • GBIO 2020
  • Fundamental
  • Price
  • PBYI $2.50
  • GBIO $2.44
  • Analyst Decision
  • PBYI Strong Buy
  • GBIO Buy
  • Analyst Count
  • PBYI 1
  • GBIO 4
  • Target Price
  • PBYI $7.00
  • GBIO $7.50
  • AVG Volume (30 Days)
  • PBYI 401.9K
  • GBIO 65.7K
  • Earning Date
  • PBYI 10-31-2024
  • GBIO 08-07-2024
  • Dividend Yield
  • PBYI N/A
  • GBIO N/A
  • EPS Growth
  • PBYI N/A
  • GBIO N/A
  • EPS
  • PBYI 0.18
  • GBIO N/A
  • Revenue
  • PBYI $219,143,000.00
  • GBIO $13,174,000.00
  • Revenue This Year
  • PBYI N/A
  • GBIO $99.36
  • Revenue Next Year
  • PBYI N/A
  • GBIO N/A
  • P/E Ratio
  • PBYI $13.74
  • GBIO N/A
  • Revenue Growth
  • PBYI N/A
  • GBIO 1397.05
  • 52 Week Low
  • PBYI $2.13
  • GBIO $0.86
  • 52 Week High
  • PBYI $7.73
  • GBIO $4.65
  • Technical
  • Relative Strength Index (RSI)
  • PBYI 42.01
  • GBIO 47.29
  • Support Level
  • PBYI $2.23
  • GBIO $2.13
  • Resistance Level
  • PBYI $2.42
  • GBIO $2.49
  • Average True Range (ATR)
  • PBYI 0.17
  • GBIO 0.23
  • MACD
  • PBYI 0.02
  • GBIO -0.01
  • Stochastic Oscillator
  • PBYI 54.00
  • GBIO 38.27

About PBYI Puma Biotechnology Inc

Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.

About GBIO Generation Bio Co.

Generation Bio Co is a genetics medicine company that is focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable highly differentiated therapeutic applications. Its first platform is a potent, highly selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.

Share on Social Networks: